Ultrasound-Derived Fat Fraction Accurately Grades Steatosis in Chronic Liver Disease

The global increase in metabolic dysfunction-associated steatotic liver disease, a condition characterized by hepatic fat accumulation linked to metabolic risk factors, has made it the most prevalent cause of chronic liver disease in Western nations [1]. While liver biopsy remains the historical reference standard for staging, its invasive nature and associated risks necessitate the development of reliable noninvasive biomarkers for routine clinical use [2, 3]. Accurate quantification of liver fat is particularly critical for patients with comorbid type 2 diabetes or obesity, who face significantly higher risks of progression to cirrhosis and hepatocellular carcinoma, or primary liver cancer [4, 5]. Current guidelines emphasize the need for accessible screening tools that can risk-stratify patients and monitor treatment response without the cost and access limitations of magnetic resonance imaging [6, 4]. A recent prospective multicenter study now offers fresh insights into the utility of a quantitative ultrasound technique for assessing hepatic steatosis, providing clinicians with a potential alternative to invasive tissue sampling.